IP Library › Patent Application 10952442
Patent Application
App. No. 10/952,442

Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/952,442
Abstract

A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.

Claims (2)

1 - 103 . (canceled)

104 . A method for treating a B cell malignancy comprising administering at least one antibody having substantial B cell depleting activity and at least one immunomodulatory antibody.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2009
From: HANNA, NABIL; HARIHARAN, KANDASAMY
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 022747/0775 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2009
From: BIOGEN IDEC INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 022602/0542 →